University of Ulm, Neurology
Welcome,         Profile    Billing    Logout  
 9 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Berthele, Achim
CALLIPER, NCT05054140 / 2021-000048-23: Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Active, not recruiting
2
450
Europe, Canada, US, RoW
IMU-838, Vidofludimus calcium, Placebo matching IMU-838, Placebo Arm
Immunic AG
Multiple Sclerosis
01/25
01/25
RED4MS, NCT06430671 / 2022-000801-28: Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Recruiting
1/2
135
Europe
CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs
Cellerys AG, Novartis, Scope International AG, Tetec AG, Jung Diagnostics GmbH
Relapsing-remitting Multiple Sclerosis (RRMS)
08/26
03/27
TRAMmoniTTR, NCT03237494: Study Genetic Screening of an At-risk Population for HATTR and Monitoring of TTR Positive Subjects

Recruiting
N/A
5000
Europe
CENTOGENE GmbH Rostock, Alnylam Pharmaceuticals
Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Polyneuropathies, Cardiomyopathies
04/25
04/25
Ludolph, Albert
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
NCT03127267 / 2019-001862-13: Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Recruiting
3
495
Europe, US, RoW
Masitinib (6.0), AB1010, Riluzole, Rilutek, Placebo, Placebo Oral Tablet, Masitinib (4.5)
AB Science
Amyotrophic Lateral Sclerosis
12/23
12/23
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Recruiting
3
45
Europe, Japan, US
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Recruiting
3
150
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
NCT05039099 / 2020-005971-11: A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Active, not recruiting
2
63
Europe, Canada, US, RoW
AP-101, Placebo
AL-S Pharma, AL-S Pharma
Amyotrophic Lateral Sclerosis
12/24
10/25
IVITOC, NCT04881682: Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting
2
20
Europe
Immunoadsorption, Immunoglobulins
University of Ulm, Miltenyi Biomedicine GmbH
CIDP
03/26
03/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
NCT05633459: A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Recruiting
1
64
Europe, Canada
Multiple ascending doses of QRL-201, Multiple ascending doses of Placebo, QRL-201, Placebo
QurAlis Corporation
Amyotrophic Lateral Sclerosis
08/26
08/26
IPET-GBS, NCT04871035: Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

Recruiting
N/A
20
Europe
Immunoadsorption, Plasma Exchange
University of Ulm, DiaMed GmbH
GBS
05/25
05/25
TRAMmoniTTR, NCT03237494: Study Genetic Screening of an At-risk Population for HATTR and Monitoring of TTR Positive Subjects

Recruiting
N/A
5000
Europe
CENTOGENE GmbH Rostock, Alnylam Pharmaceuticals
Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Polyneuropathies, Cardiomyopathies
04/25
04/25
NCT05554835: Global Registry and Natural History Study for Mitochondrial Disorders

Recruiting
N/A
6000
Europe
LMU Klinikum, European Commission, German Federal Ministry of Education and Research, University of Pisa
Mitochondrial Diseases, Kearns-Sayre Syndrome, MIDD, SANDO, SCAE, NARP Syndrome, MELAS Syndrome, MERRF Syndrome, Coenzyme Q10 Deficiency, LHON, MNGIE, MIRAS, Barth Syndrome, MDS, Mitochondrial Myopathies, Leigh Syndrome, Pearson Syndrome, CPEO
12/40
12/40
Schlotter-Weigel, Beate
TRAMmoniTTR, NCT03237494: Study Genetic Screening of an At-risk Population for HATTR and Monitoring of TTR Positive Subjects

Recruiting
N/A
5000
Europe
CENTOGENE GmbH Rostock, Alnylam Pharmaceuticals
Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Polyneuropathies, Cardiomyopathies
04/25
04/25

Download Options